Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEMBIFY to Prevent Infections in Hypogammaglobulinemia Associated With B-cell CLL, MM, and NHL
NCT05645107Phase 3Recruiting
- Sponsor
- Grifols
- Start
- Dec 2022
- Primary completion
- Aug 2029
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 8
01
Overview
A Phase 3 trial of immune globulin subcutaneous, human-klhw in hypogammaglobulinemia, bacterial infection, sponsored by Grifols. Started Dec 2022; status: recruiting.
02
Drugs
immune globulin subcutaneous, human-klhw
03
Conditions
hypogammaglobulinemiabacterial infection
Beyond the preview
Go deeper on NCT05645107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05645107.